BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/20/2021 12:49:51 PM | Browse: 1069 | Download: 1946
Publication Name World Journal of Clinical Oncology
Manuscript ID 61561
Country Saudi Arabia
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Case Report
Article Title Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report
Manuscript Source Unsolicited Manuscript
All Author List Muhammad Imran Butt, Abdulmohsen Mohammed Khalid Bakhsh and Quaid Johar Nadri
ORCID
Author(s) ORCID Number
Muhammad Imran Butt http://orcid.org/0000-0002-2143-7303
Abdulmohsen Mohammed Khalid Bakhsh http://orcid.org/0000-0003-3881-0300
Quaid Johar Nadri http://orcid.org/0000-0002-6654-4196
Funding Agency and Grant Number
Corresponding Author Muhammad Imran Butt, FRCP, MD, MRCP, Doctor, Doctor, Department of Medicine, King Faisal Specialist Hospital, Research Centre, Al Faisal University, Zahrawi St, Al Maather, Al Maazer, Riyadh 12713, Saudi Arabia. mimran74@hotmail.com
Key Words Hurthle cell thyroid cancer; Lenvatinib; Nephrotic syndrome; Vascular endothelial growth factor; Protein kinase inhibitors; Kidney neoplasms/secondary neoplasm; Case report
Core Tip The present case study provides a unique learning and case management experience. Our patient had widespread metastasis from a histopathologically low-risk thyroid cancer coupled with two decades of survival despite noniodine-avid metastasis, treatment of renal metastasis with tyrosine kinase inhibitors, and the development of multisystem adverse events, including rare nephrotic syndrome.
Publish Date 2021-04-20 12:49
Citation Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report . World J Clin Oncol 2021; 12(4): 272-281
URL https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm
DOI https://dx.doi.org/10.5306/wjco.v12.i4.272
Full Article (PDF) WJCO-12-272.pdf
Full Article (Word) WJCO-12-272.docx